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Welcome to the FSH Society 2014 International Research Consortium & Research Planning Meetings! 
 
This workshop brings together clinicians, scientists, patient representatives and policy makers to discuss the latest 
developments in facioscapulohumeral muscular dystrophy (FSHD).  For twenty years this gathering has provided 
the FSHD community with a forum to present and discuss new findings, reinforce collaborative efforts, facilitate 
new initiatives, and coordinate research and clinical activities.   
 
Impressive scientific progress has been made over the past three years and even in the past few months in our 
understanding of the disease.  This is a critically important time for the community to convene and discuss new 
data and advances in FSHD; discuss strategies to verify and independently corroborate the findings; discuss 
focusing efforts and resources in the preclinical gap and translational phase of research; improve diagnostic 
techniques and criteria for FSHD; and consider and evaluate with industry new and existing therapies for the 
disorder. 
 
Over the two days, we will revisit the priority areas identified at last year’s meeting, and discuss what we have 
achieved, what are the critical gaps that remain, and where we need to focus.  By the end of day two we should 
be able to identify whether any of last year’s priority areas should change or be modified, and if new areas should 
be considered.  
 
This meeting is organized by the FSH Society and sponsored by the Association Française Contre les Myopathies 
(AFM), aTyr Pharma, Cytokinetics, FSHD Canada, FSH Society, FSHD Global Research Foundation, Genzyme, a 
Sanofi Company, Muscular Dystrophy Association (MDAUSA), the U.S. DHHS NIH Eunice Kennedy Shriver NICHD 
Sen. Paul D. Wellstone UMMS FSHD Muscular Dystrophy Cooperative Research Center.  We thank our sponsors 
for their generous financial support. 
 
It is truly a pleasure to come together to accelerate solutions for FSHD.  Thank you for your extraordinary efforts 




Michael Altherr, PhD 
Los Alamos National Laboratory, Los Alamos, New Mexico & FSH Society Scientific Advisory Board 
 
David E. Housman, PhD 
Massachusetts Institute of Technology, Cambridge, Massachusetts & FSH Society Scientific Advisory Board 
 
Stephen J. Tapscott, MD, PhD 
Fred Hutchinson Cancer Research Center, Seattle, Washington 
 
Silvère van der Maarel, PhD 
Leiden University Medical Center, Leiden, the Netherlands 
 




Friday, October 17, 2014 
 
Registration &  
       Breakfast   8:00 a.m.-9:00 
 
Welcome   9:00-9:05 Welcome  
William Lewis, Sr., Michael Altherr, Stephen Tapscott, 
Silvere van der Maarel 
 
Review of 2013  9:05-9:20 Review of 2013/2014 priorities as stated by FSHD  
       workshop in 2013 
Moderators:  Michael Altherr, Rune Frants, Stephen Tapscott   
  
Platform Session 1  9:20-9:55 Clinical Studies  (1x15 minutes; 2x10 minutes) 
      Moderators: George Padberg, Rabi Tawil   
     9:55-10:15 Discussion 
 
Break    10:15-10:30  
 
Platform Session 2  10:30-11:30 Genetics and epigenetics  (4x15 minutes) 
      Moderators: Davide Gabellini, Richard Lemmers 
    11:30- Noon  Discussion 
 
Poster Introductions  Noon-1:00 Lunch and Poster Viewing [collect and have Lunch] 
 
Platform Session 3  1:00-1:50 Molecular mechanisms (2x15 minutes; 2x10 minutes) 
Moderators: Louis Kunkel, Rune Frants 
     1:50-2:15 Discussion 
 
Break    2:15-2:30  
 
Platform Session 4  2:30-3:40 Models (4x15 minutes; 1x10 minutes) 
Moderators: Peter Lunt, Yi-Wen Chen 
     3:40-4:00 Discussion 
 
Break    4:00-4:15  
 
Platform Session 5  4:15-5:00 Therapeutic studies (3x15 minutes) 
Moderators: Lynn Hartweck, Joel Chamberlain 
    5:00-5:30 Discussion 
 
Assembly Session  5:30-6:00 Discuss charge for Saturday’s meeting to define  
         2014/2015 research priorities, future directions, etc. 
Moderators: Michael Altherr, Rune Frants, George Padberg, 
   Stephen Tapscott, Silvere van der Maarel 
  
Adjourn     6:00 p.m. 
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Saturday, October 18, 2014 
 
Registration &  
       Breakfast   8:00 a.m.-9:00 
 
Welcome   9:00-9:05 Welcome  
William Lewis, Sr., Michael Altherr, Stephen Tapscott, 
Silvere van der Maarel 
 
Discussion and planning  9:10-12:30  International “lab meeting” 
         
 
     Planning and problem solving sessions 
 
 Moderated discussion sessions with entire group of attendees based on data presented at day 
1.  Co-chairs and organizers will meet Saturday morning before the session to help identify specific 
topics of interest to lead the discussion around.  The goals are to 1.) help identify and troubleshoot 
bottlenecks; and, 2.) define the research/clinical priorities for the next year 2014/2015. 
 
9:10-12:20 Discussions  
Moderators:  Michael Altherr and Rune Frants 
 
12:20-12:30 Finalizing listing of items, areas and priorities  
 
Lunch     12:30 -1:30 p.m.   
 















The FSH Society (Facioscapulohumeral Muscular Dystrophy) is an independent, non-profit 501(c)(3) and tax-exempt U.S. 
corporation organized to address issues and needs specifically related to facioscapulohumeral muscular dystrophy (FSHD). 
Contributions and financial donations are acknowledged for tax purposes.  All inquiries should be addressed to: FSH Society, 
Daniel Paul Perez, 450 Bedford Street, Lexington, MA 02420.  Phones: (781) 301-6650 and (781) 275-7781, fax: (781) 862-
1116, e-mail: daniel.perez@fshsociety.org, website: http://www.fshsociety.org 
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NOTES ON TALKS AND POSTERS  
 
   First Author Presenting Author Topic 
 
Platform Session 1   
   Clinical Studies   Chairs:  George Padberg, Rabi Tawil 
 
9:20-9:35 a.m.   Statland   Statland    Relevant outcome measures 
9:35 -9:45 a.m.   *Smith   Smith     Testing for FSHD2 in high-volume 
9:45-9:55 a.m.  *Strom   Boyar   Molecular combing FSHD1 
9:55-10:15 a.m.       Discussion  
 
Platform Session 2 
   Genetics and Epigenetics   Chairs:  Davide Gabellini, Richard Lemmers  
 
10:30 -10:45 a.m.  Calandra  Deidda   New methylation assay for FSHD 
10:45-11:00 a.m.  Lemmers Lemmers  CpG methylation at D4Z4 
11:00-11:15 a.m.  Zeng  Yokomori  Role D4Z4 chromatin DUX4 ORF 
11:15 -11:30 a.m.  Balog  Balog   Epigenetic requirement of DUX4 
11:30 -Noon       Discussion  
 
Platform Session 3 
   Molecular mechanisms   Chairs:  Rune Frants, Louis Kunkel 
 
1:00:1:15 p.m.   Gabellini Gabellini  Molecular char. of DBE-T lncRNA 
1:15-1:30 p.m.   Eidahl  Eidahl   Protein-protein interact of DUX4 
1:30-1:40 p.m.   *Annseau Coppee   DUX transcript. factors cytoplasm 
1:40-1:50 p.m.   *Thijssen Thijssen   DUX4 induces FRG2  
1:50-2:15 p.m.       Discussion  
 
Platform Session 4 
   Models   Chairs:   Peter Lunt, Yi-Wen Chen 
 
2:30-2:45 p.m.  Mariot  Dumonceaux  Early late correlation FAT1 
2:45-3:00 p.m.  Zavaljevski Chamberlain  “On demand” model of FSHD  
3:00-3:15 p.m.  Caron   Schmidt   Human stem cell model FSHD 
3:15-3:30 p.m.  Dandapat Hartweck  Inducible transgene encode DUX4 
3:30 -3:40 p.m.  *Morere Magdinier  hiPSCs model FSHD1 and FSHD2 
3:40 -4:00 p.m.       Discussion  
 
Platform Session 5 
   Therapeutic Studies   Chairs:  Michael Kyba, Joel Chamberlain 
 
4:15-4:30 p.m.   Pandey  Chen   Mol. factors that affect DUX4 expr 
4:30-4:45 p.m.   Sverdrup Sverdrup  Inhibition BET Blocks DUX4 
4:45-5:00 p.m.   Wallace  Wallace   DUX4 targeted RNAi-therapy 
5:00 -5:30 p.m.       Discussion  
 
Posters             [ Charron  Coppee   WNT pathway alterations   Poster 
   Derenne  Derenne   method naked DNA delivery FSHD  Poster 
   Kazakov  Kazakov   Dropped head in FSHD   Poster 
Lunt  Lunt   UK FSHD-Registry    Poster  
Tierney  Sacco   STAT3 signaling controls satellite cell Poster 
   Wauters  Coppee   Memb. proteins FSHD biomarkers  Poster   ] 
 
Talks that are asterisked (*) indicate a shorter 10 minute presentation
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Priorities as stated by FSHD Research Community for FSHD Research in 2014 at the 2013 FSH 
Society FSHD International Research Consortium, held October 21-22, 2013 at the David H. 
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 
Cambridge, Massachusetts 
 
Summary of Priorities and General Discussion, Tuesday October 22, 2013 
 
DUX4 
The unanimous conclusion of the general discussion was that overexpression of the 
toxic transcription factor Dux4 is at the root of FSHD1 and FSHD2. Expression of flDUX4 mRNA 
(and protein) is dependent on two conditions: 1. A specific DUX4 haplotype containing a poly-A 
site and 2. An open chromatin structure, due to D4Z4 repeat contraction-dependent (FSHD1) or 
contraction-independent (FSHD2) mechanisms, the latter due to mutations in the SMCHD1 
gene encoding a chromatin modulating enzyme. There are indications for further genetic 
heterogeneity, thus additional gene defects causing FSHD. 
The chromatin relaxation of the DUX4 region (close to the #4q telomere) can induce 
additional gene expression effects in cis (#4) and trans (other chromosomes). 
As Dux4 is a transcription factor, the over-expression can trigger a cascade of 
downstream molecular pathways contributing to the large variability in the clinical phenotype 
and natural history of FSHD. 
Conclusion: DUX4 expression is necessary but not always sufficient to cause FSHD. 
Research should focus on upstream and downstream molecular pathways and mechanisms as 
they form the most plausible intervention targets. 
 
Disease models 
The field needs improved and specific in vivo (animal) models for mechanistic and 
intervention studies. At this stage it is not sensible to give strict recommendations. 
Inducible (conditional) models seem necessary to dissect spatial and temporal effects of 
the DUX4 pathway. For specific questions, simpler models, like zebra fish may have unique 
potential. 
Various xenograph models aiming at generating human muscle in mouse muscle are 
promising, but strongly dependent on availability of human muscle biopsies or cell lines. In 
other muscle disease fields, AAV mediated “gene therapy” has proven its value. Availability of 
higher vertebrate models (e.g. dog, primates etc.) may be helpful to study intervention effects 
prior to human trials.  
 
Intervention 
Is there a magic bullet for FSHD treatment? Although the DUX4 over expression is 
crucial, various biological and chemical (pharma) strategies can be envisaged to intervene with 
the overall expression mechanism, directly by targeting the mRNA or the protein, or indirectly 
by modulating the transcription machinery, including the chromatin structure.  
As the ultimate goal is to influence the clinical phenotype and disease progression, 
intervention in specific molecular subpathways of the DUX4 cascade may form alternative 
strategies. 
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Clinical studies and trial readiness. 
There is an urgent need for better understanding of the natural history of FSHD, e.g. the 
clinical heterogeneity between and within families, the asymmetric expression of the disease, 
the cause and consequence of inflammation, and the effect of physical and cognitive training, 
etc. 
 
The FSHD field is working hard to establish patient databases with detailed clinical and 
genetic information. Equally, the development of sensitive quantitative clinical monitoring 
methods to follow intervention trials has a high priority.  
It is important to closely follow the situation in related fields, e.g. Duchenne, etc. 
 
The 10 Priorities 
 
• The DUX4 interactome 
• Understanding DUX4 manifestation and variation 
• Additional genetic heterogeneity; non-FSHD1 and 2 
• Disease models 
• Well documented Natural history with reliable endpoints; modulating 
mechanisms/genes 
• Increasing data depth of patient databases with extensive (follow-up) clinical data 
• Prepare for clinical trials: reliable and meaningful outcome measures; with access to 
discreet patient populations and disease mechanism of action classes. 
• Therapy; proof-of-principle experiments 
• Focus on translational research; from clinic to bench and back 
• Understanding pathophysiology of FSHD: connection to DUX4, heterogeneity, 




FSH Society FSHD International Research Consortium & Research Planning Meetings.  October 17-18, 2014 ©FSH Society  
 
     first author  presenter  topic     preference  
 
1.  Statland  Statland  Relevant outcome measures  spoken 
2.  Smith   Smith    Testing for FSHD2 in high-volume  spoken 
3.  Strom   Boyar   Molecular combing FSHD1  spoken 
4.  Calandra   Deidda   New methylation assay for FSHD spoken 
5.  Lemmers  Lemmers  CpG Methylation at D4Z4  spoken 
6..  Zeng   Yokomori  role D4Z4 chromatin DUX4 ORF  spoken 
7.  Balog  Balog   Epigenetic requirement of DUX4 spoken 
8.  Gabellini   Gabellini  Molecular char. of DBE-T lncRNA spoken 
9.  Eidahl  Eidahl   Protein-protein interact of DUX4 spoken 
10.  Ansseau    Coppee  DUX transcript. factors cytoplasm spoken 
11.  Thijssen  Thijssen  DUX4 induces FRG2   spoken 
12.  Mariot  Dumonceaux  Early late correlation FAT1  spoken 
13.  Zavaljevski Chamberlain  “On demand” model of FSHD   spoken 
14.  Caron   Schmidt  human stem cell model FSHD  spoken 
15.  Dandapat  Hartweck  inducible transgene encode DUX4 spoken 
16.  Morere  Magdinier  hiPSCs model FSHD1 and FSHD2 spoken 
17.  Pandey  Chen   Mol. factors that affect DUX4 expr spoken 
18.  Sverdrup  Sverdrup  Inhibition BET blocks DUX4  spoken 
19.  Wallace   Wallace  DUX4 targeted RNAi-based therapy spoken 
20.  Charron   Coppee  WNT pathway alterations   poster 
21.  Derenne  Derenne  method naked DNA delivery FSHD poster 
22.  Kazakov  Kazakov  Dropped head in FSHD  poster 
23.  Lunt  Lunt   UK FSHD-Registry – first 16 mos.  poster 
24.  Tierney  Sacco   STAT3 signal controls satellite cell poster 
25.  Wauters  Tassin   Memb. proteins FSHD biomarkers  poster 
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1.  Clinically Relevant Outcome Measures for Facioscapulohumeral Muscular Dystrophy 
 
Jeffrey Statland, MD 1, Katy Eichinger, PT 2, Colleen M. Donlin-Smith, MA 2, Chad Heatwole, MD 
2, and Rabi Tawil, MD 2 
 
1 University of Kansas Medical Center, Kansas City, Kansas 
2 University of Rochester Medical Center, Rochester, New York 
 
Background: As we move towards investigating new therapeutics for Facioscapulohumeral 
muscular dystrophy (FSHD) it is important to have the tools in place to conduct efficient, high 
quality clinical trials. Different outcome measures will be important at different phases in the 
drug development process: biomarkers for early phase and proof of concept studies, and 
functional and patient-reported outcomes for later phase studies. 
 
Methods: We are conducting a prospective 12 month observational study in 40 genetically 
confirmed FSHD participants to determine the reliability, concurrent validity, and 
responsiveness to FSHD disease progression of 1) an FSHD-specific patient-reported outcome 
measure; 2) an FSHD-specific clinical outcome measure (FSH-COM); and 3) a non-invasive 
biomarker of muscle structure, electrical impedance myography (EIM). Here we present 
baseline data (n=20) for the FSH-COM and EIM. Reliability is determined by the intra-class 
correlation coefficient (ICC).  The relationships between different clinical measures were 
performed using Pearson correlation coefficient (r).  The minimally detectable change is defined 
as the smallest change at which we are 90% confident the change is not due to measurement 
error (MDC90). Sample size estimates were for two independent samples with equal variance, 
two tailed, at 80% power and a level of significance of 0.05. 
 
Results: The FSH-COM shows excellent reliability with an intra-class correlation (ICC) coefficient 
of 0.97 (95% lower confidence limit [LCLM] 0.92). EIM showed reliability range (ICC) between 
0.76-0.99 for major muscle groups, but was less reliable for facial muscles.  The FSH-COM has 
moderate to strong linear relationships to clinical severity scores (clinical severity score r=0.67, 
P=0.002; FSHD clinical score r=0.78, P<0.001).  EIM reactance measurement at 100 kHz of the 
right biceps (EIM RB) showed moderate to strong relationships to the FSH-COM (r=-0.52, 
P=0.03), the FSHD clinical score (r=-0.67, P=0.002), and time to doff or don a jacket (r=-0.51, 
P=0.02).  The MDC90 for the FSH-COM is 4.8, this represents a 20.5% change from the baseline 
mean.  The number of patients needed per treatment group to detect a difference at least as 
large as the MDC90 in the FSH-COM is 100 per group.  The number of patients needed to detect 
a similar %change in the baseline EIM RB is 21 per group. 
 
Conclusion: Initial evaluation of baseline data shows excellent reliability for the FSH-COM.  EIM 
shows acceptable to excellent reliability for major muscle groups.  Both demonstrate 
concurrent validity when compared to related FSHD disease measures.  EIM for individual 
muscles (e.g. right biceps) shows potential sample size efficiency for early phase studies. 
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Study supported by FSH Society grants (FSHS-22013 and FSHS-82012), and National Institutes of 
Health (NIAMS) U01AR065119 Development of a Clinically Relevant Outcome Measure for 
FSHD Therapeutic Trials.  JS support provided by KUMC CTSA award KL2TR000119. 
12 
FSH Society FSHD International Research Consortium & Research Planning Meetings.  October 17-18, 2014 ©FSH Society  
 
2.  Testing for FSHD2 in a high-volume FSHD diagnostic service setting: pyrosequencing-based 
hypomethylation assay and SMCHD1 sequencing - the Bristol experience  
 
Debbie Smith, Jennifer Whitfield, Rebecca Whittington, Susanne O’Shea, Peter Lunt, Maggie 
Williams 
 




Bristol Genetics Laboratory has provided a UKGTN (United Kingdom Genetics Testing Network) 
specialist diagnostic service for FSHD since 1992, and processing over 400 referrals annually 
(diagnostic, exclusion, predictive and prenatal referrals) from the UK and abroad. In a seven 
year audit of 2047 diagnostic FSHD referrals, 37% showed a contraction of the D4Z4 repeat at 
4q35 including 10 individuals with two pathogenic 4qA fragments, where further haplotyping 
was required. 111 patients were referred for extended deletion testing and a deletion of the 
p13E-11 probe region was confirmed in 4 patients. The clinically typical negative patients (4.8% 
of BGL diagnostic referrals) are candidates for FSHD2 testing. 
 
Building on the work of Lemmers et al. (2012) and Hartweck et al. (2013), we have developed a 
novel pyrosequencing assay for quantification of methylation using 10 sites within DR1. A pilot 
UK cohort of 15 clinically typical FSHD1 negative patients (assessed by clinical proforma) and 
recruited/consented by geneticists/neurologists were assessed for hypomethylation by 
bisulphite conversion and pyrosequencing, followed by SMCHD1 sequencing. 9/15 patients had 
hypomethylation (defined by a 42% methylation cut off level) and candidate SMCHD1 
mutations were identified in all 9 patients (3 missense, 1 non-sense, 1 duplication, 2 deletions, 
2 potential splice site). 3 patients without hypomethylation were sequence negative. Family 
studies are on-going. 
 
The pilot study has informed diagnostic service provision and a UKGTN gene dossier application 
has supported successful commissioning of testing for FSHD2 for the UK from April 2014 
facilitating direct translation of this work into clinical service. A further 20 patients have been 
tested for FSHD2, including 3 requests for predictive testing.  
 
We present our pyrosequencing assay method and the results of the FSHD2 cohort study, set in 
the context of an audit of FSHD testing, including some interesting cases which highlight the 
clinical utility of the testing pipeline in unlocking the complexity for diagnostic interpretation 
which can sometimes be encountered.  
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3.  Molecular Combing for Facioscapulohumeral Dystrophy Type 1: Benefits of Direct 
Visualization of DNA Fibers  
 
C.M. Strom1, J.C. Wang1, X.J. Yang1, B.H. Nguyen1, V. Sulcova1, P. Chan1, Y. Liu1, A. Anguiano1, 
J.J. Higgins2, F.Z. Boyar1 
 
1 Quest Diagnostics Inc., Nichols Institute, San Juan Capistrano, California 92690, USA 
2 Quest Diagnostics Inc., Athena Diagnostics, Worcester, Massachusetts 01605, USA 
 
Facioscapulohumeral dystrophy (FSHD) is the third most common muscular dystrophy. Type-1 
FSHD is due to a contraction of the D4Z4 macrosatellite repeat motif on the subtelomere of 
chromosome 4q. Two common haplotypes exist at the 4q locus: 4qA and 4qB. D4Z4 
macrosatellite repeat motifs are also present on chromosome 10q (10qA and 10qB). 
Differentiation among alleles is important for diagnosis, as contractions of the 4qA but not the 
4qB, 10qB, or 10qB allele are associated with FSHD.  
 
Prior to the advent of molecular (DNA) combing, molecular diagnosis relied on a series of 
pulsed-field Southern blots. Molecular combing is a technique in which DNA is uniformly 
stretched and then hybridized with gene-specific probes of various colors to create a molecular 
bar code. We developed and validated a molecular combing test to identify and measure 
contractions of the 4qA allele.  
 
Here we report the first 44 suspected FSHD cases tested with the molecular combing assay in 
our laboratory. In all 44, we were able to unambiguously identify all 4q and 10q alleles and 
determine the size of the D4Z4 repeat. Of the 44 samples, 13 (30%) were clearly affected, with 
4qA repeat sizes of 3 to 8; 28 (63%) were clearly normal, with 4qA repeat sizes of 12 to 68; and 
3 (7%) had borderline results, with 4qA repeat sizes of 10 to 11. Two patients had a 4qB 
contraction and 15 had 10qA or 10qB contractions.  
 
We conclude that a molecular combing assay for FSHD is capable of determining the 4qA repeat 
size in clinical samples and differentiating the 4qA allele from 4qB, 10qA, and 10qB alleles.  
 
Since the molecular combing assay reports the copy number of 4qA repeat, it will allow 
correlation of repeat number with the timing of disease onset.
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4.  Development of a new methylation assay for FSHD diagnosis  
 
Calandra P.1, Cascino I.1, Lemmers R.J.2, Teveroni E.1, Ricci E.3, Galluzzi G.1, Monforte M.3, Tasca 
G.3, Moretti F.1, van der Maarel S.M.2, Deidda G.1 
 
1 Institute of Cell Biology and Neurobiology C.N.R.- Rome Italy 
2 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. 
3 Institute of Neurology, Catholic University School of Medicine, Rome, Italy. 
 
FSHD is linked to chromosomal 4q35 region, that contains a D4Z4 array of up to 200 units. The 
most common form, autosomal dominant FSHD1, is caused by a contraction of the 4q D4Z4 
array to less than 11 units, whereas FSHD2 is caused by reduced levels of functional SMCHD1 
protein (Structural maintenance of chromosomes flexible hinge domain-containing 1). Although 
with different mechanisms, both genetic defects lead to DNA hypomethylation at D4Z4 on 
4qter causing chromatin relaxation. This genomic modulation provides a transcriptionally 
permissive chromatin environment that is associated with the expression of DUX4 gene, the 
best candidate FSHD gene, enclosed within each D4Z4 unit. DUX4 expression requires also the 
presence of a polyadenylation signal (PAS) distal to the last D4Z4 unit that stabilizes the DUX 
transcript. There are two different allelic forms of the region distal to the D4Z4 array, A and B. 
Although a D4Z4 array followed by an A “Telomere” is also present on 10q, a functional PAS 
sequence has been identified almost exclusively on 4qA alleles. 
 
Ultimately, vast majority of FSHD1 and FSHD2 subjects show hypomethylation at D4Z4 region 
associated with an A allele containing a functional PAS. Currently, FSHD diagnosis is based on 
the identification of shortened D4Z4 4q arrays (in FSHD1) or the presence of mutations in 
SMCHD1 (in FSHD2) and the assessment of the A/B genotype of 4q alleles and eventually by 
methylation analysis at the D4Z4 units. 
 
Our study aims at developing a new diagnostic test based on the methylation analysis of CpGs 
in the region distal to the D4Z4 array. 
 
Indeed, we considered that DNA methylation changes in this distal region may correlate with 
DUX4 expression more effectively than changes in the proximal units. Therefore, we evaluated 
the relationship between the DNA methylation, disease status, repeat size and clinical severity 
by analyzing CpGs located in the close proximity of the polyadenylation signal. We have been 
able to design bisulfite sequencing assays that allow the analysis of 10 CpGs in the close 
proximity of the PAS. Results using a 4qA PAS-specific assay in a group of 38 FSHD1, 14 FSHD2 
and 18 control samples show significant differences between affected and unaffected subjects, 
supporting the potential usefulness of this assay as a diagnostic tool for FSHD diagnosis. 
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5.  Inter-individual Differences in CpG Methylation at D4Z4 Correlate with Clinical Variability 
in FSHD 
 
Richard JLF Lemmers1, Jelle J Goeman2, Patrick J van der Vliet1, Merlijn P van Nieuwenhuizen3, 
Judit Balog1, Sabrina Sacconi4, George W Padberg5, Stephen J Tapscott6, Rabi Tawil7, Bert 
Bakker3, Silvère M van der Maarel1 
 
1 Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands 
2 Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 
3 Department of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands 
4 Centre de référence des Maladies neuromusculaires and CNRS UMR6543, Nice University 
Hospital, Nice, France 
5 Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 
6 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, 
USA 
7 Department of Neurology, University of Rochester, Rochester, NY, USA 
 
FSHD is caused by contractions of the D4Z4 repeat array on chromosome 4 to 1-10 units 
(FSHD1), or by mutations in the D4Z4-binding chromatin modifier SMCHD1 (FSHD2). Both 
situations lead to a partial opening of the D4Z4 chromatin structure, and facilitate transcription 
of D4Z4-encoded polyadenylated DUX4 mRNA in skeletal muscle. The opening of the chromatin 
structure is marked by a partial loss of CpG methylation in the promoter region of the DUX4 
gene. Clinically, FSHD is marked by a high inter- and intra-familial variability that is largely 
unexplained. This clinical variability can be seen in both FSHD1 and FSHD2, suggesting a role of 
other factors besides the contracted D4Z4 repeat array or the SMCHD1 mutation. 
 
We measured CpG methylation at the FseI site of D4Z4 in a large cohort of control, FSHD1 and 
FSHD2 individuals and found a significant correlation with the D4Z4 repeat array size. After 
correction for repeat array size, we show that the variability in clinical severity in FSHD1 and 
FSHD2 individuals correlates with the level of D4Z4-CpG methylation. In FSHD1, for individuals 
with D4Z4 repeat arrays of 1-6 units, the clinical severity mainly depends on the size of the 
D4Z4 repeat. However, in individuals with arrays of 7-10 units, the clinical severity also depends 
on other factors that regulate D4Z4 methylation since affected individuals, but not non-
penetrant mutation carriers, have a greater reduction of D4Z4-CpG methylation than can be 
expected based on the size of the pathogenic D4Z4 repeat array. In FSHD2 this epigenetic 
susceptibility depends on the nature of the SMCHD1 mutation in combination with D4Z4 repeat 
array size with dominant negative mutations being more deleterious than haploinsufficiency 
mutations. With this concept of epigenetic susceptibility, we are uncovering the basis of the 
marked variability in disease onset and progression. 
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6.  Genetic and epigenetic characteristics of FSHD-associated 4q and 10q D4Z4 that are 
distinct from non-4q/10q D4Z4 homologs 
 
Weihua Zeng,1,2* Yen-Yun Chen,1* Daniel A. Newkirk,1 Beibei Wu,3 Judit Balog,4 Xiangduo Kong,1 
Alexander R. Ball, Jr.,1 Simona Zanotti,5 Rabi Tawil,6 Naohiro Hashimoto,7 Ali Mortazavi,2 Silvère 
M. van der Maarel,4 and Kyoko Yokomori1§ 
 
1 Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA 92697-
1700, USA 
2 Dept. Dev. Cell Biol., School of Biol. Sci., Univ. California, Irvine, CA 92697-2300, USA 
3 Department of Microbiology and Molecular Genetics, School of Medicine, University of California, 
Irvine, CA 92697-4025, USA 
4 Leiden University Medical Center, Center for Human and Clinical Genetics, P.O. Box 9600, 2300 RC 
Leiden, The Netherlands 
5 Neuromuscular Diseases and Neuroimmunology Unit, Muscle Cell Biology Laboratory, Fondazione 
IRCCS Istituto Neurologico "C. Besta", Via Temolo 4, 20126 Milano, Italy 
6 University of Rochester Medical Center, Rochester, NY 14642, USA 
7 Department of Regenerative Medicine, National Institute for Longevity Sciences, National Center for 
Geriatrics and Gerontology, Japan. 
(*These authors contributed equally) 
 
Facioscapulohumeral dystrophy (FSHD) is one of the most prevalent muscular dystrophies. The 
majority of FSHD cases are linked to a decreased copy number of D4Z4 macrosatellite repeats 
on chromosome 4q (FSHD1).  Less than 5% of FSHD cases have no repeat contraction (FSHD2), 
most of which are associated with mutations of SMCHD1. FSHD is associated with the 
transcriptional derepression of DUX4 encoded within the D4Z4 repeat, and SMCHD1 
contributes to its regulation.  We previously found that the loss of heterochromatin mark (i.e. 
histone H3 lysine 9 tri-methylation (H3K9me3)) at D4Z4 is a hallmark of both FSHD1 and FSHD2.  
However, whether this loss contributes to DUX4 expression was unknown.  Furthermore, 
additional D4Z4 homologs exist on multiple chromosomes, but they are largely uncharacterized 
and their relationship to 4q/10q D4Z4 was undetermined.  We found that the suppression of 
H3K9me3 results in displacement of SMCHD1 at D4Z4 and increases DUX4 expression in 
myoblasts.  The DUX4 open reading frame (ORF) is disrupted in D4Z4 homologs and their 
heterochromatin is unchanged in FSHD.  The results indicate the significance of D4Z4 
heterochromatin in DUX4 gene regulation and reveal the genetic and epigenetic distinction 
between 4q/10q D4Z4 and the non-4q/10q homologs, highlighting the special role of the 
4q/10q D4Z4 chromatin and the DUX4 ORF in FSHD. 
 
This work was supported in part by National Institutes of Health (NS069539 to S. M., AR058548 
to K. Y.), Muscular Dystrophy Association (MDA4026 to K. Y), and the FSH Society (Helen 
Younger and David Younger Fellowship Research Grant FSHS-DHY-001 to K. Y. and FSHS-DHY-
002 and FSH Society Research Fellowship grant FSHS-22011-05 to W. Z.).  D. A. N. was 
supported by the NIH T15LM07443 from the National Library of Medicine and T32-HD060555 
from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
and Y.-Y. C. by NIH T32 CA009054 from the National Cancer Institute. 
17 
FSH Society FSHD International Research Consortium & Research Planning Meetings.  October 17-18, 2014 ©FSH Society  
 
7.  Epigenetic requirement of DUX4 expression in muscle cells 
 
Judit Balog1, Peter E. Thijssen1, Sean Shadle2, Kirsten R. Straasheijm1, Patrick J. van der Vliet1, 
Yvonne D. Krom1, Annika de Jong1, Richard J.L.F Lemmers1, Rabi Tawil3, Stephen J. Tapscott2, 
Silvère M. van der Maarel1 
 
1  Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands  
2  Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, 
USA 
3  Neuromuscular Disease Unit, Department of Neurology, University of Rochester Medical 
Center, Rochester, New York, USA 
 
Recent studies have identified DUX4 (Double Homeobox 4) as a key protein in the 
pathomechanism of FSHD. DUX4 is a germline transcription factor and its ectopic expression in 
muscle initiates germline and early developmental transcriptional programs, which eventually 
lead to muscle cell death. The typical bursts of DUX4 expression in a subset of myonuclei are 
associated with local chromatin relaxation is caused either by contraction of the D4Z4 
macrosatellite array to a size of 1-10 units (FSHD1), or by mutations of SMCHD1 (FSHD2). 
Mouse Smchd1 was first identified in a ENU mutagenesis screen as a factor involved in repeat 
mediated epigenetic silencing. We aimed to elucidate the epigenetic mechanism leading to 
DUX4 transcription during in vitro myoblast differentiation. We performed expression analysis 
by RT-qPCR of 6 control, 5 FSHD1 and 9 FSHD2 myoblast-myotube pairs and determined the 
D4Z4 histone profile by ChIP-qPCR. Next we examined the effect of modulation of known D4Z4 
chromatin repressors including SUV39H1, cohesion components SMC3 and RAD21, and 
SMCHD1 in control myoblasts on DUX4 expression. Our results are supportive of a model where 
SMCHD1 is a strong epigenetic regulator of DUX4 in muscle cells.
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8.  Molecular characterization of DBE-T lncRNA driving FSHD muscular dystrophy  
 
Davide Gabellini, PhD 
 
Dulbecco Telethon Institute and Division of Regenerative Medicine, San Raffaele Scientific 
Institute, Milano, Italy 
 
Up to two thirds of the human genome is composed of repetitive sequences, which are 
dynamically transcribed producing a vast pool of non protein-coding RNA (ncRNA) molecules. 
We contributed to this field with the discovery of DBE-T, the first activating long ncRNA 
(lncRNA) involved in a human genetic disease: facioscapulohumeral muscular dystrophy (FSHD).  
 
FSHD, one of the most important neuromuscular disorders, is an autosomal dominant disease 
with a strong epigenetic component. The disease is associated with a reduced copy number of 
the D4Z4 macrosatellite repeat. We found that DBE-T is a chromatin-associated lncRNA that 
mediates a Polycomb to Trithorax epigenetic switch at the FSHD locus, driving chromatin 
remodeling and transcription of FSHD candidate genes.  
 
Here, I will summarize our recent results regarding the dynamic expression of DBE-T during 
hESC differentiation, in FSHD mouse models and in FSHD patients. The regulation of DBE-T 
expression by D4Z4 copy number, the mechanism responsible for DBE-T tethering to chromatin 
and the identification of DBE-T functional domains will be also discussed.  
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9.  Protein Chemistry and Protein-Protein Interactions of DUX4 
 
Jocelyn O. Eidahl, PhD1,3, Jian Liu, PhD1, Scott Q. Harper, PhD1,2,3 
 
1  Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital (NCH), 
Columbus, Ohio, USA 43205 
2  Department of Pediatrics, The Ohio State University (OSU) College of Medicine Columbus, 
Ohio, USA 
3  OSU/NCH Center for Muscle Health and Neuromuscular Disorders, Columbus, Ohio, USA 
 
The ultimate goal of our research is to develop treatment strategies for Facioscapulohumeral 
muscular dystrophy (FSHD). With the emergence of DUX4 as an important pathogenic insult 
underlying FSHD, we now have a viable target for therapy. Nevertheless, therapy development 
is still burdened by the lack of knowledge about how DUX4 contributes mechanistically to FSHD 
onset. Defining the biology and biochemistry of DUX4 as it relates to FSHD is a critical unmet 
need in the field. DUX4 contains two N-terminal homeodomains, which are responsible for its 
ability to bind specific DNA sequences. The DUX4 transactivation domain, consisting of C-
terminal residues 160-424, is essential for inducing muscle toxicity, however the mechanisms 
by which these residues mediate DUX4 activity are unknown. Our central hypothesis is that the 
DUX4 transcription factor is involved in protein-protein interactions, or subject to post-
translational modifications (PTMs), that influence its ability to induce toxicity in muscle cells 
and ultimately contribute to FSHD. We propose that the DUX4 C-terminal domain is involved in 
the recruitment of proteins that influence its ability to transactivate normal and toxic genes. 
We are examining DUX4’s preference for particular protein domains, as well as its ability to act 
as a ligand for known protein interaction domains. In preliminary data, we identified several 
candidate DUX4-interacting proteins and multiple PTM-modified DUX4 residues. Our goal here 
is to study DUX4 protein chemistry and identify critical interactions between DUX4 and its 
candidate binding partners. Ultimately we hope to establish a framework for developing 
therapeutic strategies that disrupt critical DUX4 protein interactions that may be required for 
its toxic effects in FSHD muscles.
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10.  Unexpected role for DUX transcription factors into the cytoplasm  
 
Eugénie Ansseau1, Christel Matteotti1, Alexandra Tassin1, Céline Lancelot1, Baptiste Leroy2, 
Céline Hubeau1, Charlotte Nachtegael1, Cécile Gerbaux1, Sabrina Zorbo1, Samuel Cloet1, 
Cassandre Yip1, Pierre Meyer3, Gilles Carnac4, Dalila Laoudj-Chenivesse4, Ruddy Wattiez2, 
Alexandra Belayew 1 and Frédérique Coppée1. 
 
1 Laboratory of Molecular Biology, Research Institute for Health Sciences and Technology, 
University of Mons, Mons, Belgium 
2 Laboratory of Proteomy and Microbiology, Research Institute for Biosciences, University of 
Mons, Mons, Belgium 
3 Pediatric Department, CHU Montpellier, France 
4 Laboratory of Physiology and experimental medicine, INSERM U1046, Montpellier, France 
 
Hundreds of double homeobox (DUX) genes map within dispersed 3.3-kb repeated elements 
and encode DNA-binding proteins. Among these we identified DUX4, a potent transcription 
factor that causes the FSHD muscular dystrophy. In the present study we identify skeletal 
muscle partners of either DUX4, DUX4c (an identical protein except for the end of the carboxyl-
terminal domain) or DUX1 (limited to the double homeodomain). We first used the yeast two-
hybrid system (Y2H) to screen an adult human skeletal muscle cDNA library with DUX1 or 
DUX4c that presented no or weak transcriptional activity in this system. We also expressed 
HaloTag-DUX4 or DUX4c fusion proteins in human muscle cells, co-purified them by affinity 
chromatography with their protein partners and identified these by mass spectrometry. We 
unexpectedly found desmin, an intermediate filament protein, other cytoskeletal proteins 
involved in actin-bundling or myofibrilar organization besides RNA-binding proteins involved in 
muscle-specific mRNA splicing and translation. Most of these partners play major roles in 
cytoskeletal organization during muscle differentiation. We confirmed DUX interaction with 
desmin as well as other partners involved in mRNA splicing by in vitro GST pull down, 
immunoprecipitation or by in situ proximal ligation assay in muscle cells. The functionality of 
these interactions was underscored by the observation of DUX4/DUX4c nucleo-cytoplasmic 
translocation upon myoblast fusion. Moreover, DUX4c and desmin immunostaining partially co-
localized in transversal muscle sections of patients affected with Duchenne Muscular 
Dystrophy. 
 
Our data suggest cytoplasmic functions for the numerous DUX gene products and identify novel 
toxicity pathways besides transcription activation for DUX4/DUX4c in FSHD muscles. 
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11.  DUX4 induces FRG2 expression by directly activating its promoter in facioscapulohumeral 
muscular dystrophy  
 
Peter E. Thijssen1, Judit Balog1, Zizhen Yao3, T. Phát Pham1, Rabi Tawil2, Stephen J. Tapscott3 
and Silvère M. Van der Maarel1  
 
1  Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands  
2  Neuromuscular Disease Unit, Department of Neurology, University of Rochester Medical 
Center, Rochester, New York, USA 
3  Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, 
USA 
 
Based on a chromatin spreading or looping model, several genes centromeric to the D4Z4 
repeat array have been considered as FSHD candidate genes. Initial reports showing 
deregulation of some of genes, including FRG1 and ANT1, could not be confirmed in 
independent studies. However, FRG2, located most proximal to the D4Z4 macrosatellite repeat, 
was reproducibly shown to be induced in differentiating myoblast cultures derived from FSHD 
patients. However, the function of FRG2 and its possible role in FSHD pathogenesis has 
remained unresolved. Sporadic activation of the DUX4 retrogene, encoded within the D4Z4 
macrosatellite repeat array, has emerged as the most likely disease model over the recent 
years. DUX4 functions as a double homeobox transcription factor and activates a specific set of 
genes upon expression in muscle cells. We now show that FRG2 is one of the direct target 
genes of DUX4 protein. Overexpression of DUX4 in proliferating primary myoblasts or 
fibroblasts results in a significant activation of FRG2 transcription. Moreover, we identified 
DUX4 binding at the FRG2 promoter by chromatin immunoprecipitation followed by deep 
sequencing. We confirmed the transactivation effect of DUX4 on the FRG2 promoter by 
luciferase reporter assays. We observed a significant increase of luciferase expression upon 
co-transfection of DUX4, which was completely ablated upon removal of the DUX4 binding sites 
in the FRG2 promoter sequence. In conclusion we show that the long known FSHD specific 
upregulation of FRG2 can be explained by the protein activity of DUX4, emphasizing its central 
role in FSHD pathogenesis  
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12.  Selectivity of early and late affected muscles in FSHD is correlated with FAT1 expression, 
which is independent of DUX4 
 
Virginie Mariot1,2,3,4, Stephane Roche5, Christophe Hourdé6, Debora Portilho1,2,3,4, Sabrina 
Sacconi7,8, Francesca Puppo5, Philippe Rameau9, Nathalie Caruso10, Anne-Lise Delezoide11, 
Claude Desnuelle7,8, Bettina Bessières12, Sophie Collardeau13, Leonard Feasson14, Thierry 
Maisonobe15, Frederique Magdinier5, Françoise Helmbacher10, Gillian Butler-Browne1,2,3,4, 
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5 Aix-Marseille Université, INSERM GMGF UMR_S910, Faculté de Médecine de la Timone, 13385 
Marseille cedex 05, France  
6 Laboratoire de Physiologie de l'Exercice (LPE). Université de Savoie, Campus Scientifique Technolac. 
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7 Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 7277, Nice 
University Hospital, Nice, France  
8 Centre de Référence des Maladies Neuromusculaires, Nice University Hospital, Nice, France  
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11 INSERM U696, Service de Biologie du Développement Hôpital Robert Debré, 75019, Paris, France  
12 INSERM U781 et Fondation IMAGINE, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants 
Malades, Département de Génétique, Paris 75015, France. Université Paris Descartes, Paris 75006, 
France 
13 Centre de pathologie Est, CHU-Lyon, 69677, Bron, France 
14 Laboratoire de Physiologie de l'Exercice - EA4338 Centre Référent Maladies Neuromusculaires Rares 
Rhône-Alpes Hôpital Bellevue CHU de St Etienne, France  
15 Groupe Hospitalier Pitié-Salpêtrière Département de Neurophysiologie Clinique, 75651 Paris cedex 13, 
France 
 
Facio-Scapulo-Humeral muscular Dystrophy (FSHD) is one of the most common inherited 
muscular diseases and is linked to either contraction of D4Z4 repeats on chromosome 4 or to 
mutations in the SMCHD1 gene on chromosome 18, leading in most cases, to the aberrant 
expression of the transcription factor DUX4. However, it remains difficult to correlate these 
genotypes with the phenotypes observed in patients such as atrophy of specific muscle groups, 
asymmetry, as well as non-muscular symptoms. Because we have recently shown that a 
transgenic mouse with a down-regulated expression of Fat1 recapitulates most of the 
phenotype observed in FSHD, we investigated expression of the human FAT1 gene in FSHD. We 
observed that FAT1 is expressed at lower levels in both adult FSHD1 and FSHD2 muscles as 
compared to control muscles. Remarkably, FAT1 expression level does not seem to be driven by 
DUX4 since (i) DUX4 mRNA down-regulation mediated by shRNA does not influence FAT1 
expression levels and (ii) levels of FAT1 mRNA were identical when comparing myotubes from 
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contracted and non-contracted clones isolated from mosaic patients, suggesting that the 
reduced level of FAT1 seen in FSHD patients is not linked to DUX4 expression, but rather to an 
individual intrinsic expression level. Finally, by comparing the endogenous expression level of 
FAT1 mRNA in 64 muscle biopsies isolated from 16 control fetuses, we observed lower 
expression levels of FAT1 in the muscles which represent early targets in FSHD patients 
compared to muscles affected at later stages, strongly suggesting a major role of FAT1 in 
targeting the muscle groups early affected in FSHD. We propose a new model for FSHD in which 
FAT1 levels may play a role in determining which muscles will exhibit early and late onset 
whereas DUX4 may rather slowly worsen the muscle phenotype. 
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13.  Development of an “on demand” model of FSHD in adult muscle 
 
Maja Zavaljevski1, Darren R. Bisset1, John K. Hall1, Stephen J. Tapscott2, Dan Miller1, and Joel R. 
Chamberlain1 
 
1 University of Washington, Seattle, Washington  
2 Fred Hutchinson Cancer Research Center, Seattle, Washington USA 
 
Contraction of the D4Z4 macrosatellite repeat on chromosome 4q35 results in low-level DUX4 
mRNA expression in skeletal muscles and is required for FSHD1 disease manifestation.  DUX4 
protein has not been detected in FSHD muscle, although its low-level expression is assumed to 
be the catalyst of pathophysiology.  Reproducing the presumably low DUX4 protein expression 
in mice to recapitulate the phenotypic features of FSHD in adult mouse muscle has proven 
challenging.  We have developed an adeno-associated viral vector (AAV) that can deliver a 
DUX4 gene expressed from its own promoter to the muscles of wild type mice.  In order to 
further characterize this model, which could enable “on demand” phenotypic induction via AAV 
DUX4, we refined virus production methods for reproducibility and also developed a method 
for DUX4 localization in cryosections.  Histological analyses of injected muscles revealed AAV 
DUX4 dose dependent tissue damage with ultrastructural properties similar to FSHD muscle, 
including focal lesions, split fibers, and regions lacking muscle fibers.  Reduction of the level of 
empty vector particles in the AAV preparations limited background damage from viral proteins.  
Injection of AAVs expressing a mutant DUX4 protein did not lead to muscle damage, nor did 
injections of vectors lacking genomes.  Our results indicate that AAV delivery of DUX4 can be 
used to generate a reproducible mouse model, both for understanding the downstream effects 
of DUX4 expression and for use in testing candidate therapies aimed at preventing and 
reversing the muscle damage. 
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14.  A human stem cell model of facioscapulohumeral muscular dystrophy (FSHD) 
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Dumevska1; Heather Main1; Davide Gabellini3; Uli Schmidt 1 
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3 Dulbecco Telethon Institute and Division of Regenerative Medicine, San Raffaele Scientific 
Institute, Milano, Italy  
4 Vita-Salute San Raffaele University, Milano, Italy  
 
Facioscapulohumeral muscular dystrophy (FSHD) presents a major unmet clinical need with no 
specific treatments being available. While significant progress was made in recent years to 
understand the complex genetics and epigenetics of the disease, research and drug discovery 
efforts would benefit from better model systems that overcome limitations of animal models 
and biopsy material. In order to develop an accurate human, scalable and consistent cellular 
disease model we created 4 human embryonic stem cell lines from donated pre-implantation 
genetic diagnosis (PGD) embryos carrying the FSHD type 1 chromosomal deletion. We 
previously reported that we used several rounds of high-content screening to establish a 
unique 3-step protocol for the differentiation of human pluripotent stem cells to skeletal 
muscle. To our knowledge, this is the world's first process that allows simple and robust 
industrial-scale cell production, achieving high yields of functional myotubes without any cell 
sorting, selection or genetic manipulation. We investigated the muscle phenotypes from 3x 
FSHD, 1x Becker muscular dystrophy and 3 normal control cell lines. FSH cell lines formed 
muscle at similar efficiencies than normal controls while Becker stem cells showed impaired 
differentiation and disorganized myotube morphology. However, we demonstrated exclusive 
expression of Dux4 in FSH-affected myotubes and found consistent morphological differences 
indicating atrophy and reduced myoblast fusion. We further analyzed expression profiles by 
mRNA microarrays and demonstrated profound changes to genes regulating the cell cycle, 
myogenesis and extracellular matrix interactions. Based on these results we are now 
developing a phenotypic high-content screening assay for drug development, and we believe 
that our unique cellular model will be a useful resource for FSHD and other muscular dystrophy 
research. 
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15.  A new mouse model for FSHD 
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To understand the effect of DUX4 in vivo, and to generate a model in which to test anti-DUX4 
therapeutics, we have introduced a doxycycline (dox)-inducible transgene encoding DUX4 and 
3′ genomic DNA into a euchromatic region of the mouse X chromosome. Although this mouse 
was intended to provide doxycycline-inducible phenotypes, through expression of DUX4, we 
found that the transgene alone, without dox, was lethal in males.  Females were runted and 
presented a skin pathology in the absence of dox.  This is due to low level leaky expression of 
the DUX4 gene, as transcript can be detected by PCR in most tissues with the most consistent 
detection in neural tissues including retina, and in testis.  We could not detect the protein in 
the absence of dox.  Although males are not usually born live, occasional males survive to term.  
These animals are much more severely affected than their female counterparts, and 
remarkably, display a retinal vascular pathology similar to that seen in FSHD.  In addition, they 
show a defect in spermatogenesis.  Muscles from these animals were composed of smaller 
fibers and were weaker, but proportionally so, and no dystrophy was present prior to death, 
invariably before 6 weeks of age.  We performed ex vivo culture experiments with myoblasts 
and muscle fibroadipogenic progenitors (FAPs) isolated from the iDUX4 males,  and found that 
high levels of dox caused cell death of myoblasts and was growth inhibitory to fibroblasts.  Low 
non-toxic levels of dox impaired differentiation of myoblasts in vitro, but had no effect on 
adipogenic differentiation of muscle FAPs.  To evaluate the effect of DUX4 expression during 
regenerative repair in vivo, we crossed the Pax7-ZsGreen satellite cell marker into this strain 
and performed transplants of satellite cells from live-born males into female NSG-mdx4Cv mice, 
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and treated recipients with varying doses of dox.  By using dystrophin staining to quantify 
engraftment, we observed a consistent and easily quantifiable dose-dependent reduction in 
regeneration by transplanted satellite cells.  These data show that DUX4 expression, even at 
low levels, is inhibitory to regenerative myogenesis.  We further propose that the quantification 
of donor-derived myofibers generated by transplanted iDUX4 satellite cells can serve as a useful 
in vivo test system for therapeutics directed against the DUX4 protein or transcript. 
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16.  Creation of a repertoire of human induced pluripotent stem cells for modeling type 1 and 
2 Facio-Scapulo-Humeral Dystrophy 
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Human induced pluripotent stem cells provide a valuable platform for investigating disease 
mechanism in vitro. In this context, we created a repertoire of induced pluripotent stem cells 
from patients clinically affected with Facio-Scapulo-Humeral Dystrophy. In most cases (95%), 
this pathology is linked to shortening of an array of macrosatellite elements at the distal 4q35 
locus. In 2-3% of patients, the pathology is associated with mutation in the SMCHD1 gene while 
in the remaining 2-3%, the cause of the pathology remains undetermined. At the molecular 
level, the pathology is associated with hypomethylation of the D4Z4 repetitive sequence and 
activation of the DUX4 retrogene.  
 
We have produced and characterized a collection of hiPSCs clones corresponding to the 
different types of patients with FSHD and investigated the D4Z4 methylation dynamics and 
DUX4 induction after reprogramming and differentiation. In parallel, we delopped a rapid and 
efficient method for differentiation toward the skeletal muscle lineages. Implication for disease 
modeling will be discussed. In conclusion, this repertoire provides us with new tools for 
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17.  Molecular factors that affect DUX4 expression and phenotypes of FSHD muscle cells in 
culture 
 
Sachchida Nand Pandey1, Hunain Khawaja1, Brinda S. Mysore1, Alexander E Liu1, Yi-Wen Chen1,2 
 
1 Research Center for Genetic Medicine, Children’s National Health System, Washington DC, 
USA 
2 Department of Integrative Systems Biology, George Washington University, Washington DC, 
USA 
 
Previous studies have reported various phenotypes of FSHD muscle cells in culture, which 
include those that are indistinguishable from healthy control myoblasts as well as abnormal 
phenotypes, such as a necrotic appearance of undifferentiated myoblasts and 
atrophic/disorganized phenotypes of differentiating myotubes. In this study, we investigated 
effects of several factors that can potentially affect DUX4 expression and/or myotube 
phenotypes in culture. These include serum and steroid that have been commonly used in cell 
culture; and few additional pharmaceutical and natural compounds. The factors tested were 1) 
serum and serum replacer (KOSR) at different concentrations; 2) steroids, including 
dexamethasone and VBP15 (a steroidal analogue which retains anti-inflammatory activity but 
lack adverse GRE-mediated transactivation); 3) three polyphenols (fisetin, punicalagin and 
gallotannin) which can potentially affect DUX4 expression and/or myotube phenotypes.  Our 
findings showed that the concentration of the serum replacer affected DUX4 expression and 
myotube phenotypes. Both dexamethasone and VBP15 suppressed DUX4 expression in culture. 
The DUX4 suppressive effect of fisetin was in a dose-dependent manner. Fisetin showed 
suppressive effects of DUX4 expression in all five concentrations tested, including 10 µM (-1.2 
fold, p<0.05), 50 µM (-1.6 fold, p<0.01), 200 µM (-5.1 fold, p<0.01), 500 µM (-8.3 fold, p<0.01) 
and 800 µM (-10.4 fold, p<0.01). The fisetin (tested at 50 µM) also showed a positive effect on 
myotube differentiation. Finally, there were dose-dependent effects on myotube 
differentiation in cells treated with punicalagin and gallotannin.  The results show that culture 
conditions significantly affect the expression of DUX4 and myotube phenotypes. The study also 
identified pharmaceutical agents and natural compounds that modulate expression of DUX4 
and improve myotubes phenotypes, which can be further tested for their therapeutic potentials 
for treating FSHD. 
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18.  Inhibition of BET Proteins Blocks DUX4 Expression FSHD Muscle Cells 
 
Francis M. Sverdrup1, Matthew P. Yates1, Sean Shadle2,  Lauren Snider2, Jon Oliva1, Silvère M. 
van der Maarel3, Rabi Tawil4, Stephen J. Tapscott2 
 
1 Center for World Health & Medicine, Saint Louis University, Saint Louis, Missouri USA 
2 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington USA 
3 Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands 
4 Neuromuscular Disease Unit, Department of Neurology, University of Rochester Medical 
Center, Rochester, New York USA 
 
Facioscapulohumeral Musclular Dystrophy (FSHD) is characterized by epigenetic changes 
resulting in the aberrant expression of the DUX4 gene in muscle. The goal of this research is to 
identify druggable targets for the promotion of epigenetic silencing and/or prevention of DUX4 
expression. We have identified the bromodomain and extra-terminal (BET) family of proteins as 
key targets involved in DUX4 expression. Selective inhibitors of BET proteins (BETi) block 
expression of DUX4 and its downstream targets in FSHD myoblasts and myotubes. To evaluate 
the therapeutic potential of BETi, we have analyzed the expression of BET family protein in 
normal and FSHD muscle cells in vitro and used siRNA knockdowns to determine which family 
member is most critical for DUX4 expression. In FSHD1 and FSHD2 myoblasts, BRD4 appears to 
play the dominant role in sustaining DUX4 expression. In addition, we have explored the 
relationship between exposure of FSHD muscle cells to BET inhibitors and the transcriptional 
response of DUX4 and its targets as well as specific markers of myoblast and myotube cell 
lineages. A 24 hour exposure to BETi results in sustained (>72h) decreases in DUX4 target gene 
expression while allowing recovery of lineage-specific gene expression in FSHD myoblasts (e.g. 
MYOD1) and myotubes (MYH2). This information is being applied to pharmacokinetic 
evaluation of BETi in mice with the goal of providing sustained muscle exposures predicted to 
elicit decreased DUX4 expression in a mouse model of DUX4 de-repression based on in vitro 
exposure-response relationships. 
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19.  Developing a DUX4-targeted RNAi-based gene therapy for FSHD 
 
Lindsay M. Wallace1,3, Jacqueline S. Domire1,3 and Scott Q. Harper1,2,3 
 
1  Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital (NCH), 
Columbus, Ohio, USA 43205 
2  Department of Pediatrics, The Ohio State University (OSU) College of Medicine Columbus, 
Ohio, USA 
3  OSU/NCH Center for Muscle Health and Neuromuscular Disorders, Columbus, Ohio, USA 
 
The emergence of DUX4 as the pathogenic insult in FSHD now makes developing targeted 
therapeutic strategies for treatment possible.  Previously our lab demonstrated proof of 
principle for the use of a DUX4-targeted RNAi-based gene therapy. In these studies an artificial 
microRNA targeted near the Hox region of DUX4 was co-delivered with pathogenic levels of 
DUX4 via adeno-associated viral (AAV) vectors. The treatment effectively reduced DUX4-
induced toxicity including prevention of fiber degeneration and loss of grip strength in mice. 
The goal of this current study is to continue down a pre-clinical path by addressing three major 
concerns of the first generation miDUX vector including 1) removal of the GFP reporter gene, 2) 
including a second miRNA specifically targeting full length DUX4 in case DUX4 short is necessary 
for normal function, and 3) determine the safety of miRNA therapy to muscle by delivering high 
doses for toxicity studies.  These continued studies provide necessary data for translating an 
RNAi-based therapy for FSHD.
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20. [P]  WNT pathway alterations in FSHD 
 
Sébastien Charron, Kelly Vancutsem, Céline Vanderplanck, Céline Lancelot, Gille Carnac*, Dalila 
Laoudj-Chenivesse*, Alexandra Belayew and Frédérique Coppée 
 
Laboratory of Molecular Biology, Health Institute, University of Mons, 6, Avenue du Champ de 
Mars, B-7000 Mons, Belgium 
*INSERM U1046 Physiologie et Médecine expérimentale Coeur et Muscle, Biosciences Institute, 
CHU A. de Villeneuve, 34295 Montpellier France 
 
DUX4 is a potent transcription factor that initiates a large gene deregulation cascade in FSHD 
muscle cells but most of the cellular pathways causing the pathology are still unknown. In 
addition, the homologous DUX4c protein is also induced in FSHD and probably contributes to 
the pathology. Different non-muscular symptoms have been reported in patients affected with 
FSHD which could be related to perturbations of the canonical/beta-catenin and/or the non-
canonical planar cell polarity (PCP) WNT pathways (1). These pathways play essential roles in 
muscle development and regeneration. 
 
In the present study, we analyzed whether the WNT pathway was altered in FSHD muscle cells. 
We first observed activation of a reporter gene for the canonical WNT pathway in FSHD and in 
DUX4- or DUX4c- overexpressing myoblasts. We then profiled mRNA expression for 84 genes 
related to the WNT pathway in control and FSHD proliferating or differentiating myoblasts. In 
healthy individuals, we identified new genes involved at the onset of muscle differentiation. 
The FSHD myotube present either an atrophic (aFSHD) or a disorganized (dFSHD) phenotype in 
a proportion that differs from one primary myoblast line to another. The aFSHD myoblasts 
presented the strongest WNT pathway mRNA deregulations with decreases in mRNAs involved 
in proliferation and in the non-canonical PCP pathway (CCND1, AP1 complex, etc.). In contrast, 
the dFSHD myocytes/myotubes presented the strongest WNT pathway mRNA deregulations 
with increases in mRNAs encoding antagonists or involved in cell proliferation (FRZB, CCND1, 
etc.) and decreases in mRNAs encoding agonists such as WNT10A. Some of the deregulated 
genes were confirmed at the protein level. Following myoblast treatment with an siRNA against 
beta-catenin the aFSHD myotubes formed upon differentiation were enlarged (similar to 
dFSHD) while the dFSHD myotubes were thinner (similar to aFSHD). 
 
In conclusion, we identified WNT pathway perturbations in both FSHD myotubes phenotypes 
but even if some WNT components were similarly altered (agonists/antagonists, receptors/co-
receptors, co-regulator of β-catenin transcriptional activity) we also identified several ones 
presenting different changes between aFSHD and dFSHD myoblasts and myotubes. Targeting 
the WNT pathways therefore seems an attractive target in therapeutic strategies for FSHD with 
the caution that the most important components to target still have to be identified and will 
most probably differ according to the pathological myotube phenotype. 
 
1. Fitzsimons RB. Neuromuscul Disord. 2011 Apr;21(4):263-71. doi: 10.1016/j.nmd.2011.02.002. 
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21. [P].  Comparison of two methods of naked DNA delivery in mice: which one is the most 
appropriate in the FSHD context?  
 
A. Derenne1, A. Tassin2, S. Conotte2, V. Jenart2, F. Coppée1, A. Belayew1, and A. Legrand2  
 
1 Laboratory of Molecular Biology, Research Institute for Health Sciences and Technology, 
University of Mons, Belgium  
2 Laboratory of Respiratory Physiology, Pathophysiology and Rehabilitation,  
 
Potential therapeutic agents (AOs, siRNA) we have developed with the aim to inhibit DUX4 
expression in muscles are promising and could contribute to the development of therapeutic 
approaches for FSHD (1). The development of animal models to assess these antisense agent 
toxicity and efficacy constitutes a next step towards clinical trials for FSHD. However no 
transgenic mouse expressing DUX4 and presenting a myopathy is available. A transgenic mouse 
that carries the D4Z4 repeat array from an FSHD allele or a control allele was described. 
However these mice do not develop a myopathy (2). Another mouse model with a doxycycline-
inducible DUX4 transgene on the X chromosome presents muscle differentiation and retina 
defects typical of FSHD but high male mortality makes it difficult to use for AO screening (3).  A 
different murine model is obtained by injection of a viral expression vector for DUX4 
(AAV.DUX4) in the TA (Tibialis Anterior) muscle. This procedure causes a local myopathy with 
several pathological features of FSHD (4). However, the development of alternative models 
avoiding the use of a viral vector remains necessary.  
 
Models based on naked DNA injection have several advantages as regards to other existing 
models (ease of naked DNA production, reproducible transgene expression pattern, no immune 
response following repeated injections). Therefore, as a non-transgenic, non-viral alternative 
for in vivo models, we have established methods allowing the expression of a transgene into 
muscles of the lower limb in the mouse. In the present study, two routes of administration 
were confronted for the first time.  Naked DNA has been injected either (i) hydrodynamically 
into the saphenous vein of the limb transiently isolated by a tourniquet (IVHD; 5-6) or (ii) 
intramuscularly in the TA, followed by an electroporation (IMEP; 7). The pcDNA-His-LACZ 
reporter vector was selected for the injections in the aim to easily monitor its expression by the 
detection of beta-galactosidase enzymatic activity on muscle tissue sections after incubation 
with its XGal substrate yielding a bright blue product. The plasmid was prepared endotoxin free 
for the injections (Plasmid Factory, Bielefeld, Germany). Different DNA doses and time-points 
were tested in triplicate in IMEP and IVHD groups. The two injection methods lead to very 
different expression patterns. The IMEP resulted in a strong B-gal expression in fibers localized 
close to the injection site, while the IVHD caused expression in scattered fibers among the 
different lower limb muscles.   
 
In conclusion, IVHD and IMEP naked DNA delivery yield different transgene expression levels 
and patterns which could both be useful in the context of an FSHD model. Indeed, the IMEP 
leads to a strong and local transgene expression which could allow an easier scoring of AO-
mediated DUX4 suppression. The IVHD results in a pattern expected in FSHD patient muscles 
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based on DUX4 stochastic expression observed in primary myoblast and myotube cultures. The 
IVHD model will thus be preferred for an investigation of pathophysiological mechanisms 
induced by DUX4 expression.  
 
References 
(1) Vanderplanck et al, PLoS One. 2011; 6(10):e26820.  
(2) Krom et al, PLoS Genet. 2013; 9(4):e1003415. 
(3) Dandapat et al Cell Rep. 2014; 11;8(5):1484-96 
(4) Wallace et al, Ann Neurol. 2011; 69(3):540-52. 
(5) Hagstrom et al, Mol Ther. 2004; 10(2):386-98 
(6) Wooddell et al, Hum Gene Ther. 2011; 22(7):889–903. 
(7) Vilquin et al, Gene Ther. 2001; 8(14):1097–107.
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22. [P]  Dropped head in FSHD patients without atrophy and weakness of neck extensor 
muscles  
 
Kazakov V.M., Rudenko D.I., Skorometz A.A., Kolynin V.O., Stuchevskay T.R. 
 
Department of Neurology, Saint-Petersburg Pavlov State Medical University and Neuromuscular 
Department, City Hospital №2, St. Petersburg, Russia  
 
Some authors previously described FSHD patients showing conspicuous dropped head caused 
by severe wasting of posterior neck muscles (Ichikawa et al. 1996). Analyzing muscle status of 
200 FSHD patients we could find slight or moderate weakness of neck extensor muscles only in 
4 of them. However some patients with severe muscle atrophy and weakness or loss of muscles 
fixing the scapulae showed visible dropped head due to abnormal posture of their shoulder 
girdle, that is sharp displacement of the shoulder girdle downwards and forwards with 
compensatory cervical spine flexion. The posterior neck muscles were normal. In several years 
the cervical spine kyphosis and contractures of shoulder internal rotator muscles developed in 
these patients. Abnormal neck posture may be a characteristic FSHD feature for some patients 
with severe deformation (abnormal posture) of the shoulder girdle due to severe affection of 
muscles fixing the scapulae without atrophy and weakness of neck extensor muscles. 
 
       Observation 47, pedigree 15, IV-3, 63 y.o. male 
 
Dropped head (or head ptosis) due to severe deformation of the shoulder girdle: sharp 
displacement of the shoulder girdle downwards and forwards, the clavicles have horizontal 
position, the axial folds go atypically from outwards to the middle of sternum, “sunken” chest 
(due to almost completely loss of muscles fixing the scapulae and pectoralis major). Slight 
atrophy of the upper lip and protrusion of the lower lip are seen due to acting of depressor labii 
inferioris muscle. Cervical spine kyphosis and contractures of subscapular and teres major 
muscles developed in this patient as well. Neck extensor muscles were normal. 
 
Ichikawa Y., Yamada H., Motoyoshi Y et al. Abnormal head drooping in facioscapulohumeral 
muscular dystrophy. Rinsho Shinkeigaku. 1996; 36: 503-506. 
Kazakov V. M.  Facio-scapulo-humeral myodystrophy (clinic and genetic). Thesis. Pavlov Medical 
Institute, Leningrad 1971,334 p. 
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23. [P].  The UK FSHD-Registry – the first 16 months 
        www.FSHD-registry.org/uk  
 
Peter Lunt  (Bristol, UK), Libby Wood1 (Newcastle, UK) , Hanns Lochmuller (Newcastle, UK),  for 
the steering committee of UK FSHD-registry.  fshdregistry@treat-nmd.eu                   
 
FSHD-Registry, Treat NMD Office, Biomedicine West Wing, International Centre for Life, 
Newcastle upon Tyne, NE1 3B , United Kingdom 
 
Introduction 
In the UK, a national registry for FSHD has been operational since May 2013. Its primary aim is 
to enable research in FSHD, including clinical trials, to be achieved more rapidly, and more 
easily.  By Sept 2014, 417 people with FSHD from across the UK have voluntarily joined, 
entering their own demographic and clinical data into the register.   
 
How do people with FSHD hear about the Registry ? 
People may first learn of the Registry through attending a specialist muscle clinic, whose staff 
are linked in to the UK Neuromuscular network, or through contact with the UK FSH-MD 
support group or the Muscular Dystrophy Campaign.  A mention of the registry may also be 
included with diagnostic laboratory reports, while the Registry web-site address ( www.FSHD-
Registry.org/uk ) will hopefully come up with search terms commonly used by someone seeking 
information about FSHD.    
 
The registry in perspective 
The 417 participants(to date) account for an estimated 14% of all people with FSHD in the UK 
(based on prevalence of 1/20,000).  Of these, 230 joined in the first 2 months, since when the 
joining rate has run at around 12-13 per month.  This ongoing rate of 150 new recruits per year 
represents 2.5/M population per year, and is still well in excess of a new diagnosis rate for FSHD 
which can be estimated at 0.67/M population per year (1/20,000 prevalence with natural 
renewal turnover expected of around 1/80th of total cases per yr).   
 
Data entry and access 
The clinical data entered includes self-reporting of age and site of onset of symptoms, 
functional disability, scapular fixation surgery and symptoms of pain.  Each person names their 
clinical specialist, who is invited to corroborate the diagnosis and enter the diagnostic  
 
DNA details 
The Registry is intended to be accessible for research studies in the UK or abroad.  There is a 
registry steering committee to whom all applications for research which would involve 
individualised participation or anonymous pooled information must first be submitted for 
approval.  For studies which are approved, the process of recruiting and consenting individual 
participants is channelled through the registry curator, enabling the researcher then to be able 
to liaise further as appropriate.  For example, a Canadian-based international  study of infantile 
and early childhood-onset FSHD has been able to recruit 10 participants from the registry.  
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The registry curator (Libby Wood) produces a regular newsletter which summarises overall data 
from the registry. Key indicators include the age and sex distribution (52%M:48%F, with 41% 
aged <40y or >70y);  hearing loss (18% overall, in 1/3rd of whom this starts at <40y);  and 
wheelchair use (18% full-time, but 45% part-time).  Recognised retinal vascular disease is rare 
(2%), but respiratory problems are reported in 12%. Persistent daily pain is experienced by 92%, 
for 2/3rds  of whom this is in the upper limb, with 53% describing this as distressing or worse 
(17% ‘horrible’ and 11% ‘excruciating’).  Scapular fixation has been performed in 10%, for whom 
74% were happy (30%) or very happy (44%) with the result, allowing improvement in the ability 
to raise the arm.  
 
Linking with other Registries 
There are now FSHD Registries in at least 9 countries across the World (UK, USA, Czech Rep., 
Italy, Egypt, Canada, France, Netherlands, Australia), collecting the same core dataset; 
therefore providing an opportunity for an international network coordinated through Treat-
NMD ( www.treat-nmd.eu ) .  The primary aim for all of these is to facilitate research, enabling 
clinical trials to be achieved more rapidly, and more easily.  
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24. [P].  STAT3 signaling controls satellite cell expansion and skeletal muscle repair 
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The progression of disease- and age-dependent skeletal muscle wasting results, in part, from a 
decline in the number and function of satellite cells (SC), the direct cellular contributors to 
muscle repair. However, little is known about the molecular effectors underlying SC impairment 
and depletion. Elevated levels of inflammatory cytokines, including Interleukin-6 (IL6), are 
associated with both age and muscle wasting conditions. Signal Transducer and Activator of 
Transcription 3 (STAT3), a downstream effector of IL6, is also elevated with muscle wasting and 
has been implicated in the regulation of self-renewal and stem cell fate in several tissues. Here 
we show that IL6-activated Stat3 signaling regulates SC behavior, promoting myogenic lineage 
progression through Myod1 regulation. Conditional ablation of Stat3 in Pax7-expressing SC 
resulted in increased expansion during regeneration, but compromised myogenic 
differentiation prevented their contribution to regenerating myofibers. In contrast, transient 
Stat3 inhibition promoted SC expansion and enhanced tissue repair in both aged and dystrophic 
muscle. Finally, the effects of STAT3 inhibition were conserved in human myoblasts. The results 
of this study indicate that pharmacological manipulation of STAT3 activity can be used to 
counteract the functional exhaustion of SC, thereby maintaining the endogenous regenerative 
response and ameliorating muscle-wasting diseases.  
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25. [P].  Membrane proteins: putative FSHD biomarkers? 
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The identification of FSHD biomarkers and their validation are essential to evaluate the 
therapeutic approach developed by our laboratory i.e. antisense tools preventing DUX4 
expression1. These FSHD biomarkers which belong to the DUX4 deregulation cascade should 
return to healthy control values upon DUX4 suppression. 
 
Fusion of FSHD primary myoblasts yields varying proportions of myotubes presenting either an 
atrophic or disorganized phenotype2. Our laboratory has compared the proteome of primary 
FSHD and control myotubes at day 4 of differentiation3. FSHD myotubes of both phenotypes 
presented a disturbance of several caveolar proteins such as PTRF (Cavin-1, Polymerase I and 
Transcript Release Factor), SDPR (Cavin-2, Serum Deprivation Response protein) and MURC 
(Cavin-4, MUscle Related Coiled-coil protein). Caveolae, considered as a subset of lipid rafts, are 
characterized by their own lipid and protein composition. Lipid rafts contain small clusters of 
GPI-anchor proteins, also increased in FSHD atrophic myotubes, such as Thy1 (Thy-1 membrane 
glycoprotein). Some proteins of the membrane repair complex were also deregulated such as 
AHNAK (Neuroblast differentiation-associated protein), MG53 (Mitsugumin 53) known to 
interact with PTRF, Dysferlin and CAV33. We have begun to validate these deregulations by 
western blot and immunofluorescence but this study would require primary myoblasts which 
are in limited supply. We decided in a first approach to use human immortalized myoblast 
clones derived from a mosaïc individual4. We received 3 clones (kindly provided by S. Van der 
Maarel and V. Mouly, Institute of Myology, Paris): a control line (54-6), and 2 lines expressing 
different amounts of DUX4 mRNA (54-A5 and 54-12). We have grown these cells and 
differentiated them for 4 days with either of two differentiation media. The first one contained 
a reduced amount of fetal bovine serum (2%) and the other one was complemented with 
insulin and apotransferrin. The cells were seeded at 2,5x105 cells/dish using 35mm matrigel-
coated dish. At day 4 after induction of differentiation, cells were immunostained with an anti-
troponinT (a differentiation marker) antibody and nuclei labelled with DAPI. The fusion index 
(MFI) was evaluated in ten fields per culture and the width of the myotubes was mesured at 
their largest place. Depending on the clone and the medium, we have observed distinct 
myotube phenotypes. The 54-12 myotubes present an atrophic phenotype and the 54-A5 
myotubes presented many clusters of nuclei in the differentiating medium with 
insulin/apotransferrin as observed in disorganized primary myotubes. 
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Thus, we could reproduce the two phenotypes typical of FSHD primary myotubes and this cell 
model is being used for the validation of the deregulated proteins identified in primary 
myotubes. 
 
1. Vanderplanck C et al. (2011) The FSHD atrophic myotube phenotype is caused by DUX4 
Expression. PLoS ONE 6. 
2. Barro M et al. (2008) Myoblasts from affected and non-affected FSHD mucles exhibit 
morphological differentiation defects. J Cell Mol Med. 14, 275-89 
3. Tassin A, Leroy B, Laoudj-Chenivesse D, Wauters A et al. (2012) FSHD myotubes with 
different phenotypes exhibit distinct proteomes. PLoS ONE. 7 
4. Krom YD et al. (2012) Generation of isogenic D4Z4 contracted and noncontracted immortal 
muscle cell clones from a mosaic patient: a cellular model for FSHD. Am J Pathol.181 : 1387-401 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
